Clinical Trials

90 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05796375 2026-01-30

ReplaceCysto

240 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

131 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06733363 2026-01-27

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

344 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

16 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT05327647 2025-12-18

BicaBCa

160 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

90 enrolled

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms

NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

30 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07189793 2025-09-24

OHAI-NMIBC-01

106 enrolled

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT04917809 2025-09-10

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07100184 2025-08-03

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

30 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06663137 2025-06-13

HGNMIBC

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07019220 2025-06-13

COBRA

47 enrolled

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT04375813 2025-05-15

eRapa

166 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

120 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04387461 2024-09-25

CORE-001

35 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT04593862 2024-09-19

BRAVE

25 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Motor Activity

NCT06310369 2024-07-22

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

50 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms

NCT06227065 2024-01-26

POLO

28 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03379909 2023-09-21

TROJAN

49 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05975151 2023-09-21

Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Phase 2 Unknown

63 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Pseudomonas Infections

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Non-Muscle Invasive Bladder Neoplasms

NCT05996952 2023-08-18

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

77 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05943379 2023-07-13

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

85 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04311580 2023-06-22

Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure

52 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03519256 2023-06-01

CheckMate 9UT

Phase 2 Terminated

142 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03549650 2022-03-04

Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms

Phase 2 Terminated

3 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Lower Urinary Tract Symptoms

NCT03719300 2020-08-19

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Phase 2 Terminated

32 enrolled 12 charts

Non-Muscle Invasive Bladder Neoplasms

NCT04498702 2020-08-13

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

41 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03950362 2019-05-16

PREVERT

Phase 2 Unknown

67 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT01687244 2017-07-24

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

40 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms

NCT02075060 2017-04-06

IPOI vs IPOP

Phase 2 Unknown

54 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02207608 2015-05-28

Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

30 enrolled 6 charts

Non-Muscle Invasive Bladder Neoplasms

NCT01731652 2015-02-10

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

12 enrolled